Please enable JS

Investors

Press Releases

 
Press Releases
  Date Title View
Oct 31, 2016
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences. 25th Annual Credit Suisse Healthcare ConferenceMonday, Novemb...
Oct 20, 2016
CAMBRIDGE, Mass., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the third quarter ended September 30, 2016 before the U.S. financial markets open on Wednesday, November 2, 2016.  ...
Sep 27, 2016
CAMBRIDGE, Mass., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Shire has exercised its right to terminate its collaboration agreement with the Company to develop and commercialize M923, a proposed ...
Sep 23, 2016
CAMBRIDGE, Mass., Sept. 23, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Corey N. Fishman to its Board of Directors effective September 22, 2016. Mr. Fishman currently serves as Chief Executive...
Aug 31, 2016
CAMBRIDGE, Mass., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will provide a corporate overview, including an update on the status of the Company's necuparanib program, at the 2016 Wells Fargo H...
Aug 4, 2016
CAMBRIDGE, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2016. For the second quarter of 2016, the Company reported total revenues of $26.4 million, including $20.7 million in product revenues from Sandoz's sale of Glatopa® ...
Aug 4, 2016
CAMBRIDGE, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Company has discontinued further accrual in its Phase 2 trial evaluating necuparanib in combination with Abraxane® and gemcita...
Jul 21, 2016
CAMBRIDGE, Mass., July 21, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the second quarter ended June 30, 2016 before the U.S. financial markets open on Thursday, August 4, 2016.  Mana...
Jun 23, 2016
CAMBRIDGE, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016.  Dr. Gilman was most recently Executive Vice P...
Jun 9, 2016
CAMBRIDGE, Mass., June 09, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the dosing of the first healthy volunteers in a Phase 1 randomized, double-blind, placebo-controlled, ascending-dose cohort study to evaluat...
FirstPrevious
4
...
NextLast
= add release to Briefcase